
About VivaChek
VivaChek is a Healthcare company based in Hangzhou (China) founded in 2013. VivaChek is engaged in developing point-of-care testing solutions. It operates on a Direct-to-Consumer (D2C) and HealthTech model. VivaChek has raised $14.21 million across 1 funding round from investors including UMC Capital. VivaChek offers products and services including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit. Its focus areas include Medical Devices and Point-of-Care Testing. Its legal entity in India is 杭州微策生物技术股份有限公司 (U99999MH1977PLC010754).
Company details
VivaChek, based in Hangzhou, China, is focused on the research, development, production, and sales of point-of-care testing (POCT) products. The company is dedicated to building an ecosystem of chronic disease management, rapid diagnostics, and digital healthcare. Solutions are provided in sectors such as blood glucose monitoring, uric acid analysis, and infectious disease detection. The aim is to become a globally trusted provider of smart POCT solutions, making health management accessible to all.
- Headquarters Hangzhou, China
- SectorsHealthcare
- Website vivachek.com.cn
- Legal Name 杭州微策生物技术股份有限公司
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$14.21M (USD)
in 1 rounds
- Latest Funding Round$14.21M (USD), Series C
Dec 2019
- Investors
Associated legal entities of VivaChek
VivaChek operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of VivaChek
VivaChek offers a comprehensive portfolio of products and services, including VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.
Blood glucose levels are monitored using this device.
Uric acid levels are measured with this analyzer.
COVID-19 antigens are detected using this test kit.
Funding Insights of VivaChek
VivaChek has successfully raised a total of $14.21M through 1 strategic funding round. The most recent funding activity was a Series C round of $14.21 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.21M
- Total Rounds 1
- Last Round Series C — $14.21M
- First Round $14.21M
(Dec 2019)
- Investors Count 1
All 1 funding rounds of VivaChek with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $14.21M | Series C | – | UMC Capital | – |
1 investors in total: 1 institutional.
Investors in VivaChek
VivaChek has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include UMC Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Semiconductors and diverse sectors are targeted by corporate-backed VC investments. | umccapital.com | Taipei, Taiwan |
Investor details for VivaChek
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of VivaChek
2 dated milestones of VivaChek across 6 years, from founding to its latest funding, stage changes and deals.
- Founded VivaChek is founded.
- Funding First funding round of $14.2M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vivachek
Complete news archive for VivaChek
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VivaChek
VivaChek was founded in 2013 and raised its 1st funding round 6 years after it was founded.
VivaChek is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
VivaChek is a funded company, having raised a total of $14.21M across 1 funding round to date. The company's 1st funding round was a Series C of $14.21M, raised on Dec 2019.
VivaChek, based in Hangzhou, China, is focused on the research, development, production, and sales of point-of-care testing (POCT) products. The company is dedicated to building an ecosystem of chronic disease management, rapid diagnostics, and digital healthcare. Solutions are provided in sectors such as blood glucose monitoring, uric acid analysis, and infectious disease detection. The aim is to become a globally trusted provider of smart POCT solutions, making health management accessible to all.
VivaChek offers VivaChek Blood Glucose Meter, VivaChek Uric Acid Analyzer, and VivaChek COVID Antigen Test Kit.
VivaChek has 1 investor. Key investors include UMC Capital.
VivaChek operates through ,.
